ArticleFrontiers in endocrinology2020
Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model.
Article in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Selective Androgen Receptor Modulators in Women: What Do We Know, and What Is Still Missing.Life (Basel, Switzerland) · 2026Review
- Anti-osteoporotic effect of sitagliptin in an osteoporosis model of ovariectomized rats: role of RUNX2 and RANKL/OPG ratio.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Effects of Combined Treatment With Selective Androgen and Estrogen Receptor Modulators Ostarine and Raloxifen on Bone Tissue In Ovariectomized Rats.Calcified tissue international · 2025Article
- Ligandrol lowers endurance and negatively affects lipid and hormonal profile of male rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The role of androgens and global and tissue-specific androgen receptor expression on body composition, exercise adaptation, and performance.Biology of sex differences · 2025Review
- Advantage of ostarine over raloxifene and their combined treatments for muscle of estrogen-deficient rats.Journal of endocrinological investigation · 2024Article
- Antiosteoporosis effect of bryodulcosigenin on ovariectomy-induced osteoporosis in experimental rats.Acta cirurgica brasileira · 2024Article
- Citrate: a key signalling molecule and therapeutic target for bone remodeling disorder.Frontiers in endocrinology · 2024Review
- Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis.Journal of bone and mineral metabolism · 2023Article
- Selective Androgen Receptor Modulators Combined with Treadmill Exercise Have No Bone Benefit in Healthy Adult Rats.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Treatment of osteoporosis using a selective androgen receptor modulator ostarine in an orchiectomized rat model.Endocrine · 2023Article
- An integrated study of hormone-related sarcopenia for modeling and comparative transcriptome in rats.Frontiers in endocrinology · 2023Article
- Ostarine-Induced Myogenic Differentiation in C2C12, L6, and Rat Muscles.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In postmenopausal women, hormonal decline changes muscle function and structure. The non-steroidal selective androgen receptor modulators (SARMs) Ostarine (OS) and Ligandrol (LG) have been shown to increase muscle mass and physical function while showing a relative low risk profile. Information about their effects on muscle structure and metabolism is lacking. To analyze this, two experiments were performed using ovariectomized rats as a standard model for postmenopausal conditions. In each experiment, 3-month old Sprague-Dawley rats were divided into five groups (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.